drugset / Trial / NCT00741845

Prevention of Persistence of Bacterial Vaginosis

NCT00741845

Phase 3 Terminated 117 enrolled Embil Pharmaceutical Co. Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.

Timeline

Start
2008-06
Primary completion
2009-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metronidazole Small molecule 37.5 mg Other
Comparator Metronidazole Small molecule 750 mg Other
Comparator Miconazole Small molecule 200 mg

Indications